Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Mar;53(6):764-765.
doi: 10.1111/apt.16271.

Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy

Giuseppe Privitera  1 , Daniela Pugliese  2 , Franco Scaldaferri  2 , Alessandro Armuzzi  1   2
Affiliations
Comment

Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy

Giuseppe Privitera et al. Aliment Pharmacol Ther. 2021 Mar.

Abstract

LINKED CONTENT

This article is linked to Al‐Ani et al papers. To view these articles, visit https://doi.org/10.1111/apt.15779 and https://doi.org/10.1111/apt.16297

PubMed Disclaimer

Comment in

Comment on

References

    1. Al‐Ani AH, Prentice RE, Rentsch CA, et al. Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient. Aliment Pharmacol Ther. 2020;52:54‐72. - PMC - PubMed
    1. Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID‐19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020;159:481‐491.e3. - PMC - PubMed
    1. Bezzio C, Saibeni S, Variola A, et al. Outcomes of COVID‐19 in 79 patients with IBD in Italy: an IG‐IBD study. Gut. 2020;69:1213‐1217. - PubMed
    1. Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID‐19 outcomes: results from an international registry. Gut. 2020. [Epub ahead of print]. 10.1136/gutjnl-2020-322539 - DOI - PMC - PubMed
    1. Privitera G, Onali S, Pugliese D, et al. Dual Targeted Therapy: a possible option for the management of refractory inflammatory bowel disease. J Crohns Colitis. 2020. [Epub ahead of print]. 10.1093/ecco-jcc/jjaa149 - DOI - PubMed